Cyclobutanone analogues of beta-lactams revisited: insights into conformational requirements for inhibition of serine- and metallo-beta-lactamases
- PMID: 20141132
- DOI: 10.1021/ja9086374
Cyclobutanone analogues of beta-lactams revisited: insights into conformational requirements for inhibition of serine- and metallo-beta-lactamases
Abstract
The most important mode of bacterial resistance to beta-lactam antibiotics is the expression of beta-lactamases. New cyclobutanone analogues of penams and penems have been prepared and evaluated for inhibition of class A, B, C, and D beta-lactamases. Inhibitors which favor conformations in which the C4 carboxylate is equatorial were found to be more potent than those in which the carboxylate is axial, and molecular modeling studies with enzyme-inhibitor complexes indicate that an equatorial orientation of the carboxylate is required for binding to beta-lactamases. An X-ray structure of OXA-10 complexed with a cyclobutanone confirms that a serine hemiketal is formed in the active site and that the inhibitor adopts the exo envelope. An unsaturated penem analogue was also found to enhance the potency of meropenem against carbapenem-resistant MBL-producing strains of Chryseobacterium meningosepticum and Stenotrophomonas maltophilia. These cyclobutanones represent the first type of reversible inhibitors to show moderate (low micromolar) inhibition of both serine- and metallo-beta-lactamases and should be considered for further development into practical inhibitors.
Similar articles
-
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.J Med Chem. 1998 Nov 5;41(23):4577-86. doi: 10.1021/jm980343w. J Med Chem. 1998. PMID: 9804697
-
Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.J Med Chem. 2003 Jun 19;46(13):2569-71. doi: 10.1021/jm034056q. J Med Chem. 2003. PMID: 12801220
-
Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams.Proteins. 2002 Apr 1;47(1):86-96. Proteins. 2002. PMID: 11870868
-
Beta-lactam antibiotic resistance: a current structural perspective.Curr Opin Microbiol. 2005 Oct;8(5):525-33. doi: 10.1016/j.mib.2005.08.016. Curr Opin Microbiol. 2005. PMID: 16129657 Review.
-
Metallo-beta-lactamase inhibitors: promise for the future?Curr Opin Investig Drugs. 2004 Aug;5(8):823-6. Curr Opin Investig Drugs. 2004. PMID: 15600238 Review.
Cited by
-
Computational analysis of the interactions of a novel cephalosporin derivative with β-lactamases.BMC Struct Biol. 2018 Oct 4;18(1):13. doi: 10.1186/s12900-018-0092-5. BMC Struct Biol. 2018. PMID: 30286754 Free PMC article.
-
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Antimicrob Agents Chemother. 2014;58(4):1835-46. doi: 10.1128/AAC.00826-13. Epub 2013 Dec 30. Antimicrob Agents Chemother. 2014. PMID: 24379206 Free PMC article. Review.
-
In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity.Int J Mol Sci. 2023 Mar 7;24(6):5120. doi: 10.3390/ijms24065120. Int J Mol Sci. 2023. PMID: 36982188 Free PMC article.
-
A review on the mechanistic details of OXA enzymes of ESKAPE pathogens.Pathog Glob Health. 2023 May;117(3):219-234. doi: 10.1080/20477724.2022.2088496. Epub 2022 Jun 26. Pathog Glob Health. 2023. PMID: 35758005 Free PMC article. Review.
-
A Lysine-Targeted Affinity Label for Serine-β-Lactamase Also Covalently Modifies New Delhi Metallo-β-lactamase-1 (NDM-1).Biochemistry. 2019 Jun 25;58(25):2834-2843. doi: 10.1021/acs.biochem.9b00393. Epub 2019 Jun 7. Biochemistry. 2019. PMID: 31145588 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous